Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pralatrexate

FDA-approved product (solution, intravenous), marketed as Folotyn, Pralatrexate.

Registered studies
44
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pralatrexate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
FDA pharmacologic class
Folate Analog Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli82.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

44registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pralatrexate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pralatrexate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

    NCT02551718 · start 2015-09-11

    Registered record
    Registry ID
    NCT02551718
    Conditions
    Recurrent Acute Leukemia of Ambiguous Lineage; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Acute Leukemia of Ambiguous Lineage
    Interventions
    Chemosensitivity Assay; Cytology Specimen Collection Procedure; Gene Expression Analysis; Genetic Variation Analysis; In Vitro Sensitivity-Directed Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-09-11
    Completion
    2021-05-13
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Acute Leukemia of Ambiguous Lineage; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia +2 more
    InterventionChemosensitivity Assay; Cytology Specimen Collection Procedure; Gene Expression Analysis; Genetic Variation Analysis +1 more
    PhaseNot applicable
    Registry statusCompleted

  • A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

    NCT03349333 · start 2015-09-10

    Registered record
    Registry ID
    NCT03349333
    Conditions
    Refractory Peripheral T-Cell Lymphoma; Relapsed T-Cell Lymphoma
    Interventions
    pralatrexate; Vitamin B12 and folic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09-10
    Completion
    2018-05-21
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Peripheral T-Cell Lymphoma; Relapsed T-Cell Lymphoma
    Interventionpralatrexate; Vitamin B12 and folic acid
    PhasePhase 3
    Registry statusCompleted

  • Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

    NCT02106650 · start 2014-07

    Registered record
    Registry ID
    NCT02106650
    Conditions
    Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    Interventions
    Folotyn and Leucovorin; Folic Acid; Vitamin B12
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    InterventionFolotyn and Leucovorin; Folic Acid; Vitamin B12
    PhasePhase 2
    Registry statusCompleted

  • Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

    NCT02013362 · start 2014-03

    Registered record
    Registry ID
    NCT02013362
    Conditions
    Peripheral T-cell Lymphoma
    Interventions
    Pralatrexate injection; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2017-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphoma
    InterventionPralatrexate injection; Vitamin B12; Folic Acid
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

    NCT01947140 · start 2013-09-09

    Registered record
    Registry ID
    NCT01947140
    Conditions
    Lymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma
    Interventions
    Pralatrexate; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2013-09-09
    Completion
    2022-09-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma +1 more
    InterventionPralatrexate; Romidepsin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

    NCT01820091 · start 2013-04

    Registered record
    Registry ID
    NCT01820091
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Folotyn; Fusilev
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2013-04
    Completion
    2015-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionFolotyn; Fusilev
    PhasePhase 1
    Registry statusWithdrawn

  • Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

    NCT01789723 · start 2013-03

    Registered record
    Registry ID
    NCT01789723
    Conditions
    Non Hodgkin's Lymphoma
    Interventions
    Fusilev; Folotyn
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2013-03
    Completion
    2015-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Hodgkin's Lymphoma
    InterventionFusilev; Folotyn
    PhasePhase 1
    Registry statusWithdrawn

  • Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

    NCT01482962 · start 2012-06-11

    Registered record
    Registry ID
    NCT01482962
    Conditions
    Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    Interventions
    Alisertib; Pralatrexate; Gemcitabine; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06-11
    Completion
    2017-12-18
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
    InterventionAlisertib; Pralatrexate; Gemcitabine; Romidepsin
    PhasePhase 3
    Registry statusCompleted

  • KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

    NCT01626664 · start 2012-06

    Registered record
    Registry ID
    NCT01626664
    Conditions
    Adult T-cell Leukemia-Lymphoma
    Interventions
    KW-0761; Pralatrexate; gemcitabine plus oxaliplatin; DHAP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2018-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult T-cell Leukemia-Lymphoma
    InterventionKW-0761; Pralatrexate; gemcitabine plus oxaliplatin; DHAP
    PhasePhase 2
    Registry statusCompleted

  • Erlotinib in Combination With Pralatrexate in Advanced Malignancies

    NCT01532011 · start 2012-03

    Registered record
    Registry ID
    NCT01532011
    Conditions
    Advanced Cancers; Solid Tumors
    Interventions
    Erlotinib; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03
    Completion
    2016-06
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers; Solid Tumors
    InterventionErlotinib; Pralatrexate
    PhasePhase 1
    Registry statusCompleted

  • Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

    NCT01420679 · start 2011-08

    Registered record
    Registry ID
    NCT01420679
    Conditions
    Peripheral T-cell Lymphoma
    Interventions
    Pralatrexate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-08
    Completion
    2017-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphoma
    InterventionPralatrexate Injection
    PhasePhase 3
    Registry statusTerminated

  • Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

    NCT01336933 · start 2011-07-06

    Registered record
    Registry ID
    NCT01336933
    Conditions
    Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
    Interventions
    prednisone; cyclophosphamide; etoposide; Vincristine; pralatrexate; laboratory biomarker analysis; comparative genomic hybridization; gene expression analysis; nucleic acid sequencing; mutation analysis; immunohistochemistry staining method; microarray analysis; RNA analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07-06
    Completion
    2016-12-28
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
    Interventionprednisone; cyclophosphamide; etoposide; Vincristine +9 more
    PhasePhase 2
    Registry statusCompleted

  • Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

    NCT01206465 · start 2010-09-14

    Registered record
    Registry ID
    NCT01206465
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    pralatrexate; fluorouracil; laboratory biomarker analysis; DNA analysis; high performance liquid chromatography; polymerase chain reaction; nucleic acid sequencing; pharmacological study; pharmacogenomic studies; polymorphism analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09-14
    Completion
    2017-06-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionpralatrexate; fluorouracil; laboratory biomarker analysis; DNA analysis +6 more
    PhasePhase 1
    Registry statusCompleted

  • Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

    NCT01178944 · start 2010-09

    Registered record
    Registry ID
    NCT01178944
    Conditions
    Adenocarcinoma of the Gastroesophageal Junction; Esophageal Undifferentiated Carcinoma; Gastric Adenocarcinoma; Gastric Squamous Cell Carcinoma; Recurrent Esophageal Adenocarcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Gastric Carcinoma; Stage IIIB Esophageal Adenocarcinoma; Stage IIIB Esophageal Squamous Cell Carcinoma; Stage IIIB Gastric Cancer; Stage IIIC Esophageal Adenocarcinoma; Stage IIIC Esophageal Squamous Cell Carcinoma; Stage IIIC Gastric Cancer; Stage IV Esophageal Adenocarcinoma; Stage IV Esophageal Squamous Cell Carcinoma; Stage IV Gastric Cancer; Undifferentiated Gastric Carcinoma
    Interventions
    Laboratory Biomarker Analysis; Oxaliplatin; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2015-11
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Gastroesophageal Junction; Esophageal Undifferentiated Carcinoma; Gastric Adenocarcinoma; Gastric Squamous Cell Carcinoma +13 more
    InterventionLaboratory Biomarker Analysis; Oxaliplatin; Pralatrexate
    PhasePhase 2
    Registry statusCompleted

  • Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

    NCT01114282 · start 2010-08

    Registered record
    Registry ID
    NCT01114282
    Conditions
    Multiple Myeloma
    Interventions
    velcade; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    Not recorded
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventionvelcade; Pralatrexate
    PhasePhase 1
    Registry statusCompleted